Reply to: “Comments on the paper ‘Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple‐negative breast cancer’ by Y. Chen et al.”

Documenti analoghi

• Comments on the paper “Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple‐negative breast cancer” by Y. Chen et al.
  di: Per Eystein Lønning, et al.
  Pubblicazione: (2025)
• Multi‐omic analysis of dysregulated pathways in triple negative breast cancer
  di: Fatima Sajjad, et al.
  Pubblicazione: (2024)
• Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency
  di: Peng Yuan, et al.
  Pubblicazione: (2024)
• Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data
  di: Rong Zhu, et al.
  Pubblicazione: (2025)
• A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair
  di: Xingxing Li, et al.
  Pubblicazione: (2025)